Get the most recent info and news about Immuron on HackerNoon, where 10k+ technologists publish stories for 4M+ monthly readers.

Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.

Immuron

immuron

Immuron Ltd (NASDAQ:IMRN, ASX:IMC) has received a bull case valuation of A$0.35 and a base case valuation of A$0.25 from Pitt Street Research in a report. The analysts highlight that the key catalysts for realising this potential shareholder value are the advancement of the company’s clinical-stage assets through the clinic with the end goal of bringing these assets to market.

Immuron receives bull case valuation of A$0.35 from Pitt Street Research

MELBOURNE, Australia, Oct. 30, 2023 (GLOBE NEWSWIRE) --  (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to advise our Chief Executive Officer,

Immuron CEO Steven Lydeamore presented at AusBioInvest

MELBOURNE, Australia, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce the second cohort of 34 participants have commenced the clinical ...

Immuron Announces Travelan® Clinical Study Cohort 2 commences

Immuron signs up second cohort for clinical trial assessing Travelan® in the prevention of travellers' diarrhoea

Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is ...

Oracle leads race to $1 trillion valuation as AI stocks and cryptocurrencies soar

Second cohort of 34 healthy volunteers enrolled in the Travelan ® Clinical Trial Clinical Trial to examine a dosing regimen for Travelan ® more suited to the US military has commenced the second ...

Immuron Limited: Immuron Announces Travelan Clinical Study Cohort 2 commences

Highlights: Second cohort of 34 healthy volunteers enrolled in the Travelan® Clinical Trial Clinical Trial to examine a dosing regimen for Travelan® more suited to the US military has commenced the

The first cohort in-patient stage of the study was completed in August 2023. Immuron received confirmation that a second cohort of 34 study participants were admitted to the Pharmaron inpatient ...

Immuron Announces Travelan® Clinical Study Cohort 2 Commences

MELBOURNE, Australia, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (IMCIMRN, an Australian based and globally integrated biopharmaceutical company, is pleased to announce the second cohort of ...

Highlights: Second cohort of 34 healthy volunteers enrolled in the Travelan® Clinical Trial Clinical Trial to examine a dosing regimen for Travelan® more suited to the US military has commenced the second cohortThe clinical study 6 month follow up of Cohorts 1 and 2 anticipated to be completed in April 2024Travelan® is known to protect against the onset of Traveler’s diarrhea (TD),

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Immuron Ltd. ADR

At the close in NYSE, the Dow... Immuron Limited (IMRN) is pleased to provide the Q3 FY23 Investor Presentation for the business update webinar to be held today at 11:00 am (AEST). The Investor ...

Immuron Ltd ADR (IMRN)

Besra Gold (ASX:BEZ) has received US$10m from Quantum Metal Recovery as part of a US$300m facility to build a mine at the ~3Moz Bau project in Malaysia’s Sarawak region. Great Boulder Resources (ASX:GBR) has intersected high grades including 8m @ 13.68g ...

In Case You Missed It: Gold sales and big gold hits take the cake

Immuron previously reported (August 9, 2023) that short term stock outages of Travelan&circledR; in some wholesalers and pharmacies in the June 2023 quarter was resolved following receipt of GMP Clearance from the Therapeutic Goods Administration (TGA).

Immuron achieves record quarterly Travelan® sales

Immuron previously reported (August 9, 2023) that short term stock outages of Travelan ® in some wholesalers and pharmacies in the June 2023 quarter was resolved following receipt of GMP Clearance from the Therapeutic Goods Administration (TGA).

Stories, News & Mentions about IMMURON

Immuron’s Stories on HackerNoon

Immuron's News & Mentions